A course of treatment with checkpoint inhibitors Yervoy (ipilimumab) and Opdivo (nivolumab) for patients with unresectable or metastatic melanoma is every 3 weeks for a total of four doses. Almost forty percent of patients receiving this combined regimen discontinue treatment because of immune-related adverse events. Continue reading
Early discontinuation of checkpoint inhibition due to immune-related side effects does not have a significant impact on treatment efficacy
Leave a reply